The Dexcom G6 Glucose Program Continuous Glucose Monitoring System (Dexcom Glucose Program System) is a real time, continuous glucose monitoring device indicated for the management of diabetes in persons age 2 years and older.

The Dexcom Glucose Program System is intended to replace fingerstick blood glucose testing for diabetes treatment decisions for persons with diabetes who are not at significant risk of severe hypoglycemia. Interpretation of the Dexcom Glucose Program System results should be based on the glucose trends and sequential sensor readings over time. The Dexcom Glucose Program System also aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating long-term therapy adjustments.

The Dexcom Glucose Program System is also intended to autonomously communicate with digitally connected devices. The Dexcom Glucose Program System can be used alone or in conjunction with these digitally connected devices or services for the purpose of managing diabetes.

Device Description

The Dexcom G6 Glucose Program Continuous Glucose Monitoring System (Dexcom Glucose Program System) is a continuous glucose monitor (CGM) that offers an altered feature set versus the predicate Dexcom G6 CGM System.

The Dexcom Glucose Program System consists of three main components: a sensor/applicator delivery system, a transmitter, and a mobile application (app). The sensor is a small and flexible wire inserted into subcutaneous tissue where it converts glucose into electrical current. The transmitter is connected to the sensor and is worn on the body. It samples the electrical current produced by the sensor and converts these measurements into glucose readings using an onboard algorithm. The transmitter sends glucose data to the app. The app displays the current glucose reading (updated every 5 minutes) and glucose trends (up to 12 hours) from the transmitter. The app alerts users of important system conditions, when it enters an error state, or when requiring the user to enter information. The app also supports connectivity to Dexcom Share and Follow (DEN140016), however, the new app is a separate device from the Share and Follow apps.

AI/ML Overview

The provided text is a U.S. FDA 510(k) summary for the Dexcom G6 Glucose Program Continuous Glucose Monitoring System. It describes the device, its intended use, and compares it to a predicate device. However, it does not contain the detailed acceptance criteria for performance, the results of a specific study proving the device meets those criteria, or information on sample sizes, ground truth establishment, or expert involvement.

The document states that the device was "verified and validated according to Dexcom's internal design control process and in accordance with special controls for integrated continuous glucose monitors" and that "This testing demonstrated that the system performed according to its specifications and that the technological and performance criteria are comparable to the predicate device."

Nonetheless, specific quantitative acceptance criteria and detailed study results are not present in the provided text. To answer your request thoroughly, this information would need to be extracted from a separate clinical study report or a more detailed section of the 510(k) submission that is not included here.

Therefore, I cannot populate the table or provide detailed information for points 2 through 9 based solely on the provided text.

Summary

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which consists of the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG" in blue, with the word "ADMINISTRATION" underneath.

October 26, 2018

Dexcom, Inc. Luke Olson Senior Specialist, Regulatory Affairs 6340 Sequence Dr. San Diego, CA 92121

Re: K182041

Trade/Device Name: Dexcom G6 Glucose Program Continuous Glucose Monitoring System Regulation Number: 21 CFR 862.1355 Regulation Name: Integrated continuous glucose monitoring system Regulatory Class: Class II Product Code: ODK Dated: July 26, 2018 Received: July 30, 2018

Dear Luke Olson:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part

{1}------------------------------------------------

801 and Part 809); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.html; good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4. Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).

Sincerely.

Kellie B. Kelm -S

for Courtney H. Lias, Ph.D. Director Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics and Radiological Health Center for Devices and Radiological Health

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K182041

Device Name

Dexcom G6 Glucose Program Continuous Glucose Monitoring System

Indications for Use (Describe)

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

510(k) Summary

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is:

A. Submitter:

Dexcom, Inc.

6340 Sequence Dr.

San Diego, CA 92121

Contact: Luke Olson

Senior Regulatory Affairs Specialist

Phone: 858.875.5307

Fax: 858.332.0204

Email: lolson@dexcom.com

Date Prepared:

B. Device Names and Classification:

Proprietary Name	Dexcom G6 Glucose Program Continuous GlucoseMonitoring System
Common Name	Integrated Continuous Glucose Monitoring System,Factory Calibrated
Class	II
Classification Regulation	21 CFR 862.1355
Product Code	QDK
Review Panel	Clinical Chemistry

C. Predicate Device:

Dexcom G6 Continuous Glucose Monitoring System (DEN170088)

D. Device Description:

{4}------------------------------------------------

Indications for Use: ن

The Dexcom Glucose Program System is intended to replace fingerstick blood glucose testing for diabetes treatment decisions for persons with diabetes who are not at significant risk of severe hypoglycemia. Interpretation of the Dexcom Glucose Program System results should be based on the glucose trends and several sequential readings over time. The Dexcom Glucose Program System also aids in the detection of episodes of hyperglycemia and hypoglycemia, facilitating long-term therapy adjustments.

The Dexcom Glucose Program System is also intended to autonomously communicate with digitally connected devices. The Dexcom Glucose Program System can be used alone or in conjunction with digitally connected devices or services for the purpose of managing diabetes.

Device	Dexcom Glucose Program System(K182041)	Dexcom G6 CGM System (DEN170088)
Trade Name	Dexcom G6 Glucose ProgramContinuous Glucose MonitoringSystem	Dexcom G6 Continuous GlucoseMonitoring System
Manufacturer	Dexcom, Inc.	Dexcom, Inc.
Indications for Use	The Dexcom G6 Glucose ProgramContinuous Glucose MonitoringSystem (Dexcom Glucose ProgramSystem) is a real time, continuousglucose monitoring device indicated	The Dexcom G6 Continuous GlucoseMonitoring System (Dexcom G6 CGMSystem) is a real time, continuousglucose monitoring device indicated forthe management of diabetes in personsage 2 years and older.
Device	Dexcom Glucose Program System(K182041)	Dexcom G6 CGM System (DEN170088)
	for the management of diabetes inpersons age 2 years and older.The Dexcom Glucose Program Systemis intended to replace fingerstickblood glucose testing for diabetestreatment decisions for persons withdiabetes who are not at significantrisk of severe hypoglycemia.Interpretation of the Dexcom GlucoseProgram System results should bebased on the glucose trends andseveral sequential readings over time.The Dexcom Glucose Program Systemalso aids in the detection of episodesof hyperglycemia and hypoglycemia,facilitating long-term therapyadjustments.The Dexcom Glucose Program Systemis also intended to autonomouslycommunicate with digitally connecteddevices. The Dexcom GlucoseProgram System can be used alone orin conjunction with digitallyconnected devices or services for thepurpose of managing diabetes.	The Dexcom G6 System is intended toreplace fingerstick blood glucose testingfor diabetes treatment decisions.Interpretation of the Dexcom G6 Systemresults should be based on the glucosetrends and several sequential readingsover time. The Dexcom G6 System alsoaids in the detection of episodes ofhyperglycemia and hypoglycemia,facilitating both acute and long-termtherapy adjustments.The Dexcom G6 System is also intendedto autonomously communicate withdigitally connected devices, includingautomated insulin dosing (AID) systems.The Dexcom G6 System can be usedalone or in conjunction with thesedigitally connected medical devices forthe purpose of managing diabetes.
Clinical application	Management of diabetes mellitus	Management of diabetes mellitus
Clinical setting/sitesof use	Home use	Home use
Principle ofOperation	Amperometric measurement ofcurrent proportional to glucoseconcentration in interstitial fluid viaglucose oxidase chemical reaction	Amperometric measurement of currentproportional to glucose concentration ininterstitial fluid via glucose oxidasechemical reaction
Data Presented	Estimated Glucose Value (EGV): TheEGV is the nominal glucose valuepresented to the user.Glucose Trend: Based off the glucoserate of change, users are shown theirglucose trend with a correspondingarrow.Historical Glucose Data: Users canview their previous six, or twelve	Estimated Glucose Value (EGV): The EGVis the nominal glucose value presented tothe user.Glucose Trend: Based off the glucoserate of change, users are shown theirglucose trend with a correspondingarrow.Historical Glucose Data: Users can viewtheir previous three, six, twelve, ortwenty-four hours of glucose data
Device	Dexcom Glucose Program System(K182041)	Dexcom G6 CGM System (DEN170088)
	hours of glucose data on a graph withhigh/low glucose thresholds.Time in Range: Users can view thepercent of time they spend in theirtarget glucose range based on theirconfigured high/low glucosethresholds.
Features	Connect to Dexcom Share: Users canshare their glucose data with up tothree followers.Chat with Wellness Coach: Users canchat with a third-party wellness coachfor encouragement, education, andmotivation regarding their diabetesmanagement.	Connect to Dexcom Share: Users canshare their glucose data with up to fivefollowers.
Human Factors	Easy to understand UI/UX.Commonly understood navigationtools and features.Color-coded graphics.	Easy to understand UI/UX.Commonly understood navigation toolsand features.Color-coded graphics.
Compatibility withintendedenvironments	Compatible with the Samsung J3Compatible with Android OS version7.0 and above	Compatible with iPhone 5S throughiPhone X, Samsung Note 5, Note 8,Galaxy S6-S9, J3, Google Pixel, LG G5-G6Compatible with Android OS version 7.0and above, and iOS version 10.3.2 andabove

F. Comparison with the Predicate Device:

{5}------------------------------------------------

{6}------------------------------------------------

F. Summary of Performance Testing

The Dexcom Glucose Program System was verified and validated according to Dexcom's internal design control process and in accordance with special controls for integrated continuous glucose monitors. This testing demonstrated that the system performed according to its specifications and that the technological and performance criteria are comparable to the predicate device.

G. Conclusions Drawn from Performance Testing

The Dexcom Glucose Program System is substantially equivalent to the Dexcom G6 Continuous Glucose Monitoring System as they are identical with regard to intended use and there are no differences in technological characteristics that raise different questions of safety and effectiveness. The Dexcom Glucose Program System provides a feature set

{7}------------------------------------------------

designed to help persons who are not at significant risk of severe hypoglycemia manage their diabetes.

Regulation Number and Section

§ 862.1355 Integrated continuous glucose monitoring system.

(a)
Identification. An integrated continuous glucose monitoring system (iCGM) is intended to automatically measure glucose in bodily fluids continuously or frequently for a specified period of time. iCGM systems are designed to reliably and securely transmit glucose measurement data to digitally connected devices, including automated insulin dosing systems, and are intended to be used alone or in conjunction with these digitally connected medical devices for the purpose of managing a disease or condition related to glycemic control.(b)
Classification. Class II (special controls). The special controls for this device are:(1) Design verification and validation must include the following:
(i) Robust clinical data demonstrating the accuracy of the device in the intended use population.
(ii) The clinical data must include a comparison between iCGM values and blood glucose values in specimens collected in parallel that are measured on an FDA-accepted laboratory-based glucose measurement method that is precise and accurate, and that is traceable to a higher order (
e.g., an internationally recognized reference material and/or method).(iii) The clinical data must be obtained from a clinical study designed to fully represent the performance of the device throughout the intended use population and throughout the measuring range of the device.
(iv) Clinical study results must demonstrate consistent analytical and clinical performance throughout the sensor wear period.
(v) Clinical study results in the adult population must meet the following performance requirements:
(A) For all iCGM measurements less than 70 milligrams/deciliter (mg/dL), the percentage of iCGM measurements within ±15 mg/dL of the corresponding blood glucose value must be calculated, and the lower one-sided 95 percent confidence bound must exceed 85 percent.
(B) For all iCGM measurements from 70 mg/dL to 180 mg/dL, the percentage of iCGM measurements within ±15 percent of the corresponding blood glucose value must be calculated, and the lower one-sided 95 percent confidence bound must exceed 70 percent.
(C) For all iCGM measurements greater than 180 mg/dL, the percentage of iCGM measurements within ±15 percent of the corresponding blood glucose value must be calculated, and the lower one-sided 95 percent confidence bound must exceed 80 percent.
(D) For all iCGM measurements less than 70 mg/dL, the percentage of iCGM measurements within ±40 mg/dL of the corresponding blood glucose value must be calculated, and the lower one-sided 95 percent confidence bound must exceed 98 percent.
(E) For all iCGM measurements from 70 mg/dL to 180 mg/dL, the percentage of iCGM measurements within ±40 percent of the corresponding blood glucose value must be calculated, and the lower one-sided 95 percent confidence bound must exceed 99 percent.
(F) For all iCGM measurements greater than180 mg/dL, the percentage of iCGM measurements within ±40 percent of the corresponding blood glucose value must be calculated, and the lower one-sided 95 percent confidence bound must exceed 99 percent.
(G) Throughout the device measuring range, the percentage of iCGM measurements within ±20 percent of the corresponding blood glucose value must be calculated, and the lower one-sided 95 percent confidence bound must exceed 87 percent.
(H) When iCGM values are less than 70 mg/dL, no corresponding blood glucose value shall read above 180 mg/dL.
(I) When iCGM values are greater than 180 mg/dL, no corresponding blood glucose value shall read less than 70 mg/dL.
(J) There shall be no more than 1 percent of iCGM measurements that indicate a positive glucose rate of change greater than 1 mg/dL per minute (/min) when the corresponding true negative glucose rate of change is less than −2 mg/dL/min as determined by the corresponding blood glucose measurements.
(K) There shall be no more than 1 percent of iCGM measurements that indicate a negative glucose rate of change less than −1 mg/dL/min when the corresponding true positive glucose rate of change is greater than 2 mg/dL/min as determined by the corresponding blood glucose measurements.
(vi) Data demonstrating similar accuracy and rate of change performance of the iCGM in the pediatric population as compared to that in the adult population, or alternatively a clinical and/or technical justification for why pediatric data are not needed, must be provided and determined by FDA to be acceptable and appropriate.
(vii) Data must demonstrate that throughout the claimed sensor life, the device does not allow clinically significant gaps in sensor data availability that would prevent any digitally connected devices from achieving their intended use.
(2) Design verification and validation must include a detailed strategy to ensure secure and reliable means of iCGM data transmission to provide real-time glucose readings at clinically meaningful time intervals to devices intended to receive the iCGM glucose data.
(3) Design verification and validation must include adequate controls established during manufacturing and at product release to ensure the released product meets the performance specifications as defined in paragraphs (b)(1) and (b)(2) of this section.
(4) The device must demonstrate clinically acceptable performance in the presence of clinically relevant levels of potential interfering substances that are reasonably present in the intended use population, including but not limited to endogenous substances and metabolites, foods, dietary supplements, and medications.
(5) The device must include appropriate measures to ensure that disposable sensors cannot be used beyond its claimed sensor wear period.
(6) Design verification and validation must include results obtained through a usability study that demonstrates that the intended user can use the device safely and obtain the expected glucose measurement accuracy.
(7) The labeling required under § 809.10(b) of this chapter must include a separate description of the following sensor performance data observed in the clinical study performed in conformance with paragraph (b)(1) of this section for each intended use population, in addition to separate sensor performance data for each different iCGM insertion or use sites (
e.g., abdomen, arm, buttock):(i) A description of the accuracy in the following blood glucose concentration ranges: less than 54 mg/dL, 54 mg/dL to less than 70 mg/dL, 70 to 180 mg/dL, greater than 180 to 250 mg/dL, and greater than 250 mg/dL.
(ii) A description of the accuracy of positive and negative rate of change data.
(iii) A description of the frequency and duration of gaps in sensor data.
(iv) A description of the true, false, missed, and correct alert rates and a description of the available glucose concentration alert settings, if applicable.
(v) A description of the observed duration of iCGM life for the device.